Torii Ryo, Yamasaki Kei, Ishiguro Yutaka, Shingu Tatsuya, Hata Ryosuke, Yatera Kazuhiro
Department of Respiratory Medicine Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan Kitakyushu Japan.
Department of Respiratory Medicine University of Occupational and Environmental Health, Japan Kitakyushu Japan.
Respirol Case Rep. 2025 May 26;13(5):e70218. doi: 10.1002/rcr2.70218. eCollection 2025 May.
We present a patient with recurrent pneumothorax induced by lenvatinib, used for the treatment of thymic carcinoma. A 76-year-old Japanese man, who is a current smoker, was diagnosed with thymic carcinoma with pulmonary metastasis and pleural dissemination. Lenvatinib was initiated as third-line chemotherapy in April 2022. He was subsequently admitted to our hospital in August and October 2023 for recurrent left-sided pneumothorax. Following the second left pneumothorax, lenvatinib was discontinued, and he has remained free of pneumothorax for over a year. Clinicians should be aware of the potential adverse effects of lenvatinib in patients with pulmonary metastasis or pleural dissemination.
我们报告了一例由乐伐替尼诱发复发性气胸的患者，该患者使用乐伐替尼治疗胸腺癌。一名76岁的日本男性，目前仍在吸烟，被诊断为伴有肺转移和胸膜播散的胸腺癌。2022年4月开始使用乐伐替尼作为三线化疗药物。随后，他于2023年8月和10月因复发性左侧气胸入住我院。在第二次左侧气胸发作后，停用了乐伐替尼，此后他已超过一年未再发生气胸。临床医生应意识到乐伐替尼对伴有肺转移或胸膜播散患者的潜在不良反应。
Zotero 插件